Enzyme and Receptor Antagonists for Preventing Toxicity from the Gamma‐Hydroxybutyric Acid Precursor 1,4‐Butanediol in CD‐1 Mice

Publisher Website
Google Scholar
Abstract
1,4‐Butanediol (1,4‐BD), the diol alcohol precursor of gamma‐hydroxybutyric acid (GHB), undergoes in vivo enzymatic biotransformation to GHB by alcohol dehydrogenase (ADH) and aldehyde dehydrogenase. The subsequent metabolite, GHB, is pharmacologically active at GABAB and GHB receptors. GHB can be metabolized in vivo to gamma‐aminobutyric acid (GABA) and trans‐4‐hydroxycrotonic acid (T‐HCA), which are also pharmacologically active at GABAB receptors and GHB receptors, respectively. Therefore, we speculate that 1,4‐BD overdose toxicity can be prevented or attenuated with the ADH enzyme inhibitor 4‐methylpyrazole (4‐MP) as well as with CGP‐35348 and NCS‐382, novel high‐affinity receptor antagonists of GABAB receptors and GHB receptors, respectively. In our murine model of acute 1,4‐BD overdose, pretreatment of CD‐1 mice with 4‐MP significantly attenuated increases in blood GHB concentrations and prevented loss of the righting reflex and failure of the rotarod test. Also, pretreatment with CGP‐35348 and its combination with NCS‐382 significantly decreased the duration of failure for the rotarod test and the percentage of animals failing the rotarod test, respectively. However, pretreatment of CD‐1 mice with NCS‐382 alone produced prolonged failure of the rotarod test, an unexpected synergistic effect with 1,4‐BD and presumably GHB, which has not previously been demonstrated.